PressFebruary 2, 2024 Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C.
PressFebruary 2, 2024 Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
PressFebruary 2, 2024 Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
PressFebruary 2, 2024 PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
PressJanuary 31, 2024 Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
PressJanuary 31, 2024 Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
PressJanuary 31, 2024 Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders
PressJanuary 31, 2024 PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
PressJanuary 30, 2024 FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
PressJanuary 30, 2024 Huxley Health Inc. Provides Corporate Update – Appoints Bruce Linton as Chairman
PressJanuary 30, 2024 MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder
PressJanuary 29, 2024 Nirvana Life Sciences Inc. Announces Receipt of First North American Production of SOSA, a Patented, WHO Approved, Herbal Treatment for Opiate Addiction
PressJanuary 26, 2024 Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
PressJanuary 26, 2024 PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada.
PressJanuary 25, 2024 Red Light Holland Announces Strategic Changes and Launch of SR Wholesale North America, a Fresh Mushroom Sales Division
PressJanuary 24, 2024 Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
